Prostate cancer mortality in Taiwanese men: Increasing age-standardized trend in general population and increased risk in diabetic men

References

• Pu YS, Chiang HS, Lin CC, Huang CY, Huang KH, Chen J. Changing trends of prostate cancer in Asia. Aging Male. 2004;7:120–32.
   PubMedGoogle Scholar
• Chang CK, Yu HJ, Chan KW, Lai MK. Secular trend and age-period-cohort analysis of prostate cancer mortality in Taiwan. J Urol. 1997;158:1845–8.
   PubMed Web of Science ®Google Scholar
• Colli JL, Amling CL. Exploring causes for declining prostate cancer mortality rates in the United States. Urol Oncol. 2008;26:627–33.
   Google Scholar
• Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia. 2004;47:1071–8.
   PubMed Web of Science ®Google Scholar
• Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:2056–62.
   PubMed Web of Science ®Google Scholar
• Ragozzino M, Melton LJ III, Chu CP, Palumbo PJ. Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. J Chronic Dis. 1982;35:13–19.
   PubMedGoogle Scholar
• Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, . Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst. 1997;89:1360–5.
   PubMed Web of Science ®Google Scholar
• Weiderpass E, Ye W, Vainio H, Kaaks R, Adami HO. Reduced risk of prostate cancer among patients with diabetes mellitus. Int J Cancer. 2002;102:258–61.
   Google Scholar
• Waters KM, Henderson BE, Stram DO, Wan P, Kolonel LN, Haiman CA. Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol. 2009;169:937–45.
   PubMedGoogle Scholar
• Kasper JS, Liu Y, Giovannucci E. Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer. 2009;124:1398–403.
   PubMed Web of Science ®Google Scholar
• Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Antidiabetic medication and prostate cancer risk: a population-based case-control study. Am J Epidemiol. 2008;168:925–31.
   PubMed Web of Science ®Google Scholar
• Pierce BL, Plymate S, Ostrander EA, Stanford JL. Diabetes mellitus and prostate cancer risk. Prostate. 2008;68:1126–32.
   PubMed Web of Science ®Google Scholar
• Darbinian JA, Ferrara AM, Van Den Eeden SK, Quesenberry CP Jr, Fireman B, Habel LA. Glycemic status and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008; 17:628–35.
   PubMedGoogle Scholar
• Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol. 2005;161:147–52.
   PubMed Web of Science ®Google Scholar
• Leitzmann MF, Ahn J, Albanes D, Hsing AW, Schatzkin A, Chang SC, ; Prostate, Lung, Colorectal, and Ovarian Trial Project Team. Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control. 2008;19:1267–76.
   PubMed Web of Science ®Google Scholar
• Mishina T, Watanabe H, Araki H, Nakao M. Epidemiological study of prostatic cancer by matched-pair analysis. Prostate. 1985;6:423–36.
   PubMed Web of Science ®Google Scholar
• Li Q, Kuriyama S, Kakizaki M, Yan H, Sone T, Nagai M, . History of diabetes mellitus and the risk of prostate cancer: the Ohsaki Cohort Study. Cancer Causes Control. 2010;21:1025–32.
   PubMed Web of Science ®Google Scholar
• Hubbard JS, Rohrmann S, Landis PK, Metter EJ, Muller DC, Andres R, . Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging. Urology. 2004;63:253–8.
   PubMed Web of Science ®Google Scholar
• Hsing AW, Chua S Jr, Gao YT, Gentzschein E, Chang L, Deng J, . Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst. 2001;93:783–9.
   PubMedGoogle Scholar
• Tseng CH. Mortality and causes of death in a national sample of diabetic patients in Taiwan. Diabetes Care. 2004;27:1605–9.
   PubMed Web of Science ®Google Scholar
• Tseng CH. Parental diabetes in Taiwanese diabetic women with and without previous gestational diabetes. Eur J Clin Invest. 2008;38:555–61.
   Google Scholar
• Tseng CH, Tseng CP, Chong CK, Huang TP, Song YM, Chou CW, . Increasing incidence of diagnosed type 2 diabetes in Taiwan: analysis of data from a national cohort. Diabetologia. 2006;49:1755–60.
   PubMed Web of Science ®Google Scholar
• Stein KB, Snyder CF, Barone BB, Yeh HC, Peairs KS, Derr RL, . Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus: a systematic review and meta-analysis. Dig Dis Sci. 2010;55:1839–51.
   PubMed Web of Science ®Google Scholar
• Kasper JS, Liu Y, Pollak MN, Rifai N, Giovannucci E. Hormonal profile of diabetic men and the potential link to prostate cancer. Cancer Causes Control. 2008;19:703–10.
   Google Scholar
• Hsing AW, Sakoda LC, Chua S Jr. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr. 2007;86:s843–57.
   PubMed Web of Science ®Google Scholar
• Fukui M, Tanaka M, Kadono M, Imai S, Hasegawa G, Yoshikawa T, . Serum prostate-specific antigen levels in men with type 2 diabetes. Diabetes Care. 2008;31:930–1.
   PubMed Web of Science ®Google Scholar
• Werny DM, Saraiya M, Gregg EW. Prostate-specific antigen values in diabetic and nondiabetic US men, 2001–2002. Am J Epidemiol. 2006;164:978–83.
   Google Scholar
• Segars LW, Lea AR. Assessing prescriptions for statins in ambulatory diabetic patients in the United States: a national, cross-sectional study. Clin Ther. 2008;30:2159–66.
   Google Scholar
• Winkelmayer WC, Asslaber M, Bucsics A, Burkhardt T, Schautzer A, Wieninger P, .; Pharmacoeconomics Advisory Council of the Austrian Sickness Funds. Impact of reimbursement changes on statin use among patients with diabetes in Austria. Wien Klin Wochenschr. 2010;122:89–94.
   Google Scholar
• Teeling M, Bennett K, Feely J. The influence of guidelines on the use of statins: analysis of prescribing trends 1998–2002. Br J Clin Pharmacol. 2005;59:227–32.
   Google Scholar
• Chiang CW, Chiu HF, Chen CY, Wu HL, Yang CY. Trends in the use of lipid-lowering drugs by outpatients with diabetes in Taiwan, 1997–2003. Pharmacoepidemiol Drug Saf. 2008;17:62–9.
   Google Scholar
• Weinstein SJ, Mackrain K, Stolzenberg-Solomon RZ, Selhub J, Virtamo J, Albanes D. Serum creatinine and prostate cancer risk in a prospective study. Cancer Epidemiol Biomarkers Prev. 2009;18:2643–9.
   Google Scholar
• Williams ME. Diabetic CKD/ESRD 2010: a progress report? Semin Dial. 2010;23:129–33.
   Google Scholar
• Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32:1620–5.
   PubMed Web of Science ®Google Scholar
• García-Rodríguez LA, Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology. 2001;12:88–93.
   PubMed Web of Science ®Google Scholar
• Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29:254–8.
   PubMed Web of Science ®Google Scholar